When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
STEIN Fireside Podcast: Dr. Jeffrey Raskin on Advancing Pediatric Pain Surgery and Neuromodulation, S1-Ep15 In this episode of the STEIN Fireside Podcast, Drs. Klassen and Miller sits down…
Katarina Rukavina, MD, PhD, Movement Disorders Hospital, Beelitz, Germany, shares insights and guidance for palliative care for patients with Lewy body dementia. Dr Rukavina discusses the importance of…
This webinar introduces key updates in acute ischemic stroke management, focusing on how modern decision‑making integrates time‑sensitive evaluation, advanced imaging, and AI‑supported tools. It also reviews the expanded…
